iifl-logo-icon 1
IIFL

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

  • Open Demat with exclusive Advice & Services
  • Get a dedicated Relationship Manager to help you grow your wealth
  • Exclusive advisory on 20+ trading & wealth-based investment options
  • One tap Investments, Automated trading & much more
  • Minimum 1 lakh margin required
sidebar image

Q3FY24 Review: PI Industries: Exports slowing down

13 Feb 2024 , 02:29 PM

Though PI Industries (PI) reported numbers came in strong, it was led by consolidation of pharma business and one-time benefit from recovery of theft material (Rs700mn in sales). The key earnings driver CSM business CSM growth slowed down to 13%YoY (from 33% in Q1 and 22% in Q2) despite driven by driven by volume growth and ramp up in newly commercialised products. Management has maintained ~18-20% growth guidance and expects ramp up in pharma business to be gradual. Lower tax rate is likely to continue for one more year. Analysts of IIFL Securities raise FY24-25 earnings by 2-6% on the back of lower tax rate (14- 15%) and cut FY26 earnings by 3%. Their TP rolled forward to Mar’25 comes down marginally to Rs3,485 (30x Mar’26ii P/E). 

CSM growth slowing down: 

On a reported basis, PI delivered sales/Ebitda/Pat growth of 17%/33%/27%YoY. The performance consists of Pharma revenues and one-time benefit from recovery of theft material. Adjusting for pharma revenues, sales growth would have been 9.7%YoY. CSM growth slowed down to 13%YoY despite driven by volumes and ramp up in newly commercialised products. CSM order book too declined by US$100mn to $1.7bn. Domestic business declined by 6% due to delayed and erratic spread of monsoon. 

Development expenses drags pharma profitability: 

Pharma business revenues stood at ~Rs1.27bn, however Ebitda was just Rs4mn. As per the management, pro-forma EBITDA for M9FY24, before development spends of ~Rs350mn stood at ~16%. The development spends will be continued for couple of quarters, post which profitability is expected to pick up. 

Outperformance ending soon: 

PI delivered sales/Ebitda/pat growth of 20%/31%/38% during M9FY24 while the industry peers struggled with destocking and price corrections. Such outperformance came on the back of robust 22% growth in the CSM business (2/3rd of revenues) which will run into high base from Q1’25 onwards. This coupled with the weak guidance by Kumiai Chemicals on Axeev (Pyroxasulfone, 3yr Cagr of 4.8%) will create headwinds in FY25.

Related Tags

  • PI Industries
sidebar mobile

BLOGS AND PERSONAL FINANCE

Read More
Knowledge Centerplus
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Securities Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Knowledge Centerplus

Follow us on

facebooktwitterrssyoutubeinstagramlinkedin

2024, IIFL Securities Ltd. All Rights Reserved

ATTENTION INVESTORS
  • Prevent Unauthorized Transactions in your demat / trading account Update your Mobile Number/ email Id with your stock broker / Depository Participant. Receive information of your transactions directly from Exchanges on your mobile / email at the end of day and alerts on your registered mobile for all debits and other important transactions in your demat account directly from NSDL/ CDSL on the same day." - Issued in the interest of investors.
  • KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.
  • No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account."

www.indiainfoline.com is part of the IIFL Group, a leading financial services player and a diversified NBFC. The site provides comprehensive and real time information on Indian corporates, sectors, financial markets and economy. On the site we feature industry and political leaders, entrepreneurs, and trend setters. The research, personal finance and market tutorial sections are widely followed by students, academia, corporates and investors among others.

RISK DISCLOSURE ON DERIVATIVES
  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to Rs. 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.
Copyright © IIFL Securities Ltd. All rights Reserved.

Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248

plus
We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.

closeIcon

Get better recommendations & make better investments

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp